Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

Additional key appointments add expertise in clinical operations, corporate strategy and project leadership - BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a ...

Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets

This precision oncology developer reported a notable insider sale during a period of robust share price gains.

CU festival shines spotlight on tango music and dance

A festival that brings together dancers, musicians and people interested in learning more about Argentine tango music is ...
Business Wire

Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Company Focused on the Next Generation of Targeted Cancer ...

- Leading institutional investors commit $186 million through a common stock private investment in public equity (“PIPE”) led by Boxer Capital - Total proceeds expected to be approximately $353 ...

Tango Appoints Rob Eroh as Chief Product Officer and Cole Bowman as Chief Revenue Officer

Experienced enterprise software leaders join Tango to advance product strategy, accelerate revenue growth, and deliver ...